Continued listing for Molycorp on the NYSE is looking increasingly unlikely, as the company's net losses mount up. While it now has liabilities of $1.79bn, production and sales volumes continue to increase and the company's creditors are sustaining both their industry caution and patience.
Consistently low rare earths prices and operational difficulties have made Molycorp's mission to become a sustainable domestic supplier of rare earths to the US extremely difficult and punished the company's share price, which has fallen from a peak of $74.22/share in April 2011, to around $0.80/share over the past month.
© 2001-2024 Fundación Dialnet · Todos los derechos reservados